Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Detection of (154)Eu in patients post (153)Sm-EDTMP therapy using a clinical gamma camera.

Hayes JJ, Pfund J, Zouain N.

Health Phys. 2010 Mar;98(3):537-41. doi: 10.1097/HP.0b013e3181be3610.

PMID:
20147793
2.
3.

Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.

Anderson P, Nuñez R.

Expert Rev Anticancer Ther. 2007 Nov;7(11):1517-27. Review.

PMID:
18020921
4.

Samarium-153 EDTMP for metastatic bone pain palliation: the impact of europium impurities.

Kalef-Ezra JA, Valakis ST, Pallada S.

Phys Med. 2015 Feb;31(1):104-7. doi: 10.1016/j.ejmp.2014.10.078. Epub 2014 Nov 13.

PMID:
25454155
6.

Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP.

Marcus CS, Saeed S, Mlikotic A, Mishkin F, Pham HL, Javellana T, Diestelhorst S, Minami C.

Clin Nucl Med. 2002 Jun;27(6):427-30.

PMID:
12045435
7.

(153)Sm-EDTMP appears to accumulate only trivially within peritoneal ascites.

Schreck GA, Niederkohr RD.

J Nucl Med Technol. 2012 Mar;40(1):50-1. doi: 10.2967/jnmt.111.097220. Epub 2012 Jan 10.

8.

Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach.

Bruland OS, Skretting A, Solheim OP, Aas M.

Acta Oncol. 1996;35(3):381-4.

PMID:
8679270
9.

Efficacy and toxicity of 153samarium-EDTMP in painful breast cancer bone metastases.

Dolezal J.

Onkologie. 2009 Feb;32(1-2):35-9. doi: 10.1159/000184746. Epub 2009 Jan 20.

PMID:
19209017
10.

High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma.

Franzius C, Bielack S, Sciuk J, Vollet B, Jürgens H, Schober O.

Nuklearmedizin. 1999;38(8):337-40.

PMID:
10615669
11.

Bone uptake studies in rabbits before and after high-dose treatment with 153Sm-EDTMP or 186Re-HEDP.

Brenner W, Kampen WU, Brümmer C, von Forstner C, Zuhayra M, Czech N, Muhle C, Henze E.

J Nucl Med. 2003 Feb;44(2):247-51.

12.

High-dose treatment with (186)Re-HEDP or (153)Sm-EDTMP combined with amifostine in a rabbit model.

Brenner W, Kampen WU, von Forstner C, Brümmer C, Zuhayra M, Muhle C, Czech N, Henze E.

J Nucl Med. 2001 Oct;42(10):1545-50.

13.

[Primary investigation of dose-effect relationship of 153Sm-EDTMP in treating multiple bone metastases].

Fan W, Chen LX, Liu XW, Tang Q, Wang GH, Zhi SF, Zeng ZY.

Ai Zheng. 2006 Nov;25(11):1395-8. Chinese.

PMID:
17094908
14.

High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma.

Franzius C, Bielack S, Flege S, Eckardt J, Sciuk J, Jürgens H, Schober O.

Nuklearmedizin. 2001 Dec;40(6):215-20.

PMID:
11797510
15.
16.

Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease.

Coronado M, Redondo A, Coya J, Espinosa E, Couto RM, Zamora P, Marin MD, Castelo B, Lillo ME, Frutos L, Barón MG, Curto LM.

Clin Nucl Med. 2006 Oct;31(10):605-10.

PMID:
16985364
17.

Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP.

van Rensburg AJ, Alberts AS, Louw WK.

J Nucl Med. 1998 Dec;39(12):2110-5.

18.

ESR dosimetry of 89Sr and 153Sm in bone.

Kinoshita A, Braga FJ, Graeff CF, Baffa O.

Appl Radiat Isot. 2001 Feb;54(2):269-74.

PMID:
11200888
19.

Samarium-153-EDTMP dosimetry.

Heggie JC.

J Nucl Med. 1994 Jan;35(1):191-2. No abstract available.

20.

Supplemental Content

Support Center